Skip to main content
. 2020 Jan 29;9(3):e014908. doi: 10.1161/JAHA.119.014908

Figure 2.

Figure 2

Effects of sodium‐glucose cotransporter 2 inhibition on death and cause‐specific cardiovascular (CV) events for patients with (estimated glomerular filtration rate [eGFR] <60 mL/min per 1.73 m2) and without (eGFR >60 mL/min per 1.73 m2) reduced kidney function at baseline. HF indicates heart failure; MACE, major adverse cardiac event. *Indicates subgroup event numbers not available for Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients (EMPA‐REG Outcome).